US7435802B2
(en)
*
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
US20140212413A1
(en)
*
|
1995-12-11 |
2014-07-31 |
New York University |
Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
*
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US9249229B2
(en)
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
WO2002059280A2
(en)
|
2000-12-08 |
2002-08-01 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20160279239A1
(en)
*
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US8188231B2
(en)
*
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8093357B2
(en)
*
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
*
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20040175359A1
(en)
*
|
2002-11-12 |
2004-09-09 |
Desjarlais John Rudolph |
Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
|
CA2512729C
(en)
*
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
CA2517848A1
(en)
*
|
2003-01-21 |
2004-08-05 |
The Trustees Of The University Of Pennsylvania |
Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
|
US8084582B2
(en)
*
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
AT500650B1
(en)
*
|
2003-04-17 |
2009-11-15 |
Altropus Gmbh |
IMMUNOGENIC RECOMBINANT ANTIBODY
|
US20040235029A1
(en)
*
|
2003-04-28 |
2004-11-25 |
Lee Jae Moon |
In vitro translation system
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
KR20120090094A
(en)
*
|
2003-06-13 |
2012-08-16 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Aglycosyl anti-cd154(cd-40 ligand) antibodies and uses thereof
|
SI1644412T2
(en)
*
|
2003-07-01 |
2018-11-30 |
Ucb Biopharma Sprl |
Modified antibody fab fragments
|
EP1653801A4
(en)
*
|
2003-07-26 |
2007-05-30 |
Biogen Idec Inc |
Altered antibodies having improved antigen-binding affinity
|
AU2011253611B2
(en)
*
|
2003-07-26 |
2012-07-12 |
Biogen Idec Ma Inc. |
Altered Antibodies Having Improved Antigen-Binding Affinity
|
NZ545776A
(en)
|
2003-08-22 |
2009-05-31 |
Biogen Idec Inc |
Improved antibodies having altered effector function and methods for making the same
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
CA2545603A1
(en)
*
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
ATE555133T1
(en)
*
|
2003-11-13 |
2012-05-15 |
Hanmi Holdings Co Ltd |
IGG FC FRAGMENT FOR A MEDICINAL CARRIER AND METHOD FOR THE PRODUCTION THEREOF
|
US20050142133A1
(en)
*
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
US20060122784A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for augmenting a humoral immune response
|
US20060116824A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Ishikawa Muriel Y |
System and method for modulating a humoral immune response
|
US20060047433A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to enhancing an immune system
|
US20060047434A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to improving an immune system
|
US20060047437A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for heightening an immune response
|
US20060122783A1
(en)
*
|
2004-08-24 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for heightening a humoral immune response
|
US20060047436A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for magnifying an immune response
|
US20060047435A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to augmenting an immune system
|
US20060182742A1
(en)
*
|
2004-08-24 |
2006-08-17 |
Ishikawa Muriel Y |
System and method for magnifying a humoral immune response
|
KR101151477B1
(en)
|
2003-12-10 |
2012-06-22 |
메다렉스, 인코포레이티드 |
Interferon alpha antibodies and their uses
|
KR20060135690A
(en)
|
2003-12-10 |
2006-12-29 |
메다렉스, 인코포레이티드 |
Ip-10 antibodies and their uses
|
CA2561264A1
(en)
*
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
EP2357201B1
(en)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Anti-P-selectin antibodies
|
KR101297146B1
(en)
|
2004-05-10 |
2013-08-21 |
마크로제닉스, 인크. |
HUMANIZED FcγRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
ES2526194T3
(en)
|
2004-06-21 |
2015-01-08 |
E. R. Squibb & Sons, L.L.C. |
Interferon alfa 1 receptor antibodies, and their uses
|
ATE486610T1
(en)
|
2004-07-09 |
2010-11-15 |
Chugai Pharmaceutical Co Ltd |
ANTI-GLYPICAN-3 ANTIBODIES
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
CA2575838A1
(en)
|
2004-07-26 |
2006-03-30 |
Biogen Idec Ma Inc. |
Anti-cd154 antibodies
|
ES2426816T3
(en)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Fc regions variants
|
EP1784424A4
(en)
|
2004-08-16 |
2009-03-18 |
Medimmune Inc |
Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
|
US20070265819A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for improving cell-mediated immune response
|
US20070196362A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to bolster an immune response
|
US20060047439A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for improving a humoral immune response
|
DK1800693T3
(en)
|
2004-08-24 |
2013-10-21 |
Chugai Pharmaceutical Co Ltd |
Adjuvant therapy using anti-glypican 3 antibodies
|
US20070198196A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to ameliorating an immune system
|
US20070265818A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for heightening cell-mediated immune response
|
JP4958555B2
(en)
*
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
Stabilized human IgG4 antibody
|
RU2451030C2
(en)
|
2004-10-26 |
2012-05-20 |
Чугаи Сейяку Кабусики Кайся |
Anti-glypican 3-antibody having modified sugar chain
|
EP1810035A4
(en)
*
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
Engineering fc antibody regions to confer effector function
|
US9200079B2
(en)
*
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
GB0425972D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Celltech R&D Ltd |
Biological products
|
EP1674479A1
(en)
*
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
EP1838735A2
(en)
*
|
2004-12-31 |
2007-10-03 |
Genentech, Inc. |
Polypeptides that bind br3 and uses thereof
|
JP2008531060A
(en)
|
2005-03-04 |
2008-08-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
A method for humanizing immunoglobulin variable regions via rational modification of complementarity determining residues
|
US20110123440A1
(en)
*
|
2005-03-29 |
2011-05-26 |
Genevieve Hansen |
Altered Antibody FC Regions and Uses Thereof
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
JP5255435B2
(en)
|
2005-04-26 |
2013-08-07 |
メディミューン,エルエルシー |
Regulation of antibody effector function by hinge domain manipulation
|
CA2607147C
(en)
|
2005-05-09 |
2018-07-17 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
EP1899379B1
(en)
|
2005-06-20 |
2018-04-11 |
E. R. Squibb & Sons, L.L.C. |
Cd19 antibodies and their uses
|
EP1899477A4
(en)
|
2005-07-01 |
2010-01-20 |
Medimmune Inc |
An integrated approach for generating multidomain protein therapeutics
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
CA2652434A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized proteins that target ep-cam
|
SG164379A1
(en)
*
|
2005-07-21 |
2010-09-29 |
Genmab As |
Potency assays for antibody drug substance binding to an fc receptor
|
CA2618681C
(en)
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
CA2625619A1
(en)
|
2005-10-14 |
2007-04-26 |
Medimmune, Inc. |
Cell display of antibody libraries
|
US20070087005A1
(en)
*
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
EP2532679B1
(en)
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
CN101356195B
(en)
|
2005-12-08 |
2013-04-03 |
米德列斯公司 |
Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
|
GB0525214D0
(en)
|
2005-12-12 |
2006-01-18 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
BRPI0707126A2
(en)
|
2006-01-12 |
2011-04-19 |
Alexion Pharma Inc |
ox-2 / cd200 antibodies and use of these
|
CA2644903A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
CN105177091A
(en)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
Antibody modification method for purifying bispecific antibody
|
WO2007114319A1
(en)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Method for control of blood kinetics of antibody
|
AU2007248628B2
(en)
*
|
2006-05-03 |
2013-02-07 |
The Regents Of The University Of Colorado, A Body Corporate |
CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
US8367113B2
(en)
|
2006-05-15 |
2013-02-05 |
Massachusetts Institute Of Technology |
Polymers for functional particles
|
EP2021029B1
(en)
|
2006-05-26 |
2014-06-11 |
MacroGenics, Inc. |
Humanized fc gamma riib-specific antibodies and methods of use thereof
|
EP2032159B1
(en)
*
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
Fc riib-specific antibodies and methods of use thereof
|
JP5622390B2
(en)
|
2006-07-18 |
2014-11-12 |
サノフイ |
Anti-EPHA2 antagonist antibody for cancer treatment
|
WO2008018641A1
(en)
|
2006-08-11 |
2008-02-14 |
Ono Pharmaceutical Co., Ltd. |
Monoclonal antibodies against stromal derived factor-1 (sdf-1)
|
ES2402591T3
(en)
|
2006-08-14 |
2013-05-07 |
Xencor Inc. |
Optimized antibodies that target CD19
|
MX2009002418A
(en)
|
2006-09-05 |
2009-04-23 |
Medarex Inc |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use.
|
EP1900752A1
(en)
*
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
|
AU2007299843B2
(en)
|
2006-09-18 |
2012-03-08 |
Xencor, Inc |
Optimized antibodies that target HM1.24
|
RS55740B1
(en)
|
2006-10-02 |
2017-07-31 |
Squibb & Sons Inc |
Human antibodies that bind cxcr4 and uses thereof
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
PL2068922T3
(en)
|
2006-10-19 |
2012-11-30 |
Csl Ltd |
Anti-il-13r alpha 1 antibodies and their uses thereof
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
CN101578296A
(en)
|
2006-11-15 |
2009-11-11 |
梅达雷克斯公司 |
Human monoclonal antibodies to BTLA and methods of use
|
US20100303723A1
(en)
*
|
2006-11-20 |
2010-12-02 |
Massachusetts Institute Of Technology |
Drug delivery systems using fc fragments
|
CL2007003411A1
(en)
|
2006-11-28 |
2008-07-04 |
Centelion |
PROTEIN FUSION THAT CONSISTS IN AN FC REGION OF AN IMMUNOGLOBULIN WITH A FRAGMENT OR SOLUBLE DOMAIN OF A RECEIVER FOR FGF; POLINUCLEOTIDO THAT CODIFIES AND VECTOR AND CELL THAT UNDERSTAND IT; PHARMACEUTICAL COMPOSITION INCLUDING PROTEIN FU
|
ES2523915T5
(en)
*
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Variant Target Binding Agents and Uses Thereof
|
CN103172743B
(en)
|
2006-12-01 |
2015-04-08 |
梅达雷克斯有限责任公司 |
Human Antibodies That Bind Cd22 And Uses Thereof
|
US7858752B2
(en)
*
|
2006-12-05 |
2010-12-28 |
Abbott Laboratories |
Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
CL2007003622A1
(en)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
EP2447719B1
(en)
|
2007-02-26 |
2016-08-24 |
Oxford BioTherapeutics Ltd |
Proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2599791A1
(en)
*
|
2007-04-27 |
2013-06-05 |
Genentech, Inc. |
Potent, stable and non-immunosuppressive anti-CD4 antibodies
|
WO2008137915A2
(en)
|
2007-05-07 |
2008-11-13 |
Medimmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
PT2173381E
(en)
*
|
2007-05-14 |
2013-12-13 |
Novimmune Sa |
Fc receptor-binding polypeptides with modified effector functions
|
AU2008260498B2
(en)
|
2007-05-30 |
2012-11-29 |
Xencor, Inc. |
Methods and compositions for inhibiting CD32b expressing cells
|
WO2008145142A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
CA2688490C
(en)
|
2007-06-01 |
2022-06-21 |
Scott E. Strome |
Immunoglobulin constant region fc receptor binding agents
|
BRPI0814645A2
(en)
*
|
2007-07-25 |
2015-01-27 |
Alexion Pharma Inc |
METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE.
|
PE20140196A1
(en)
*
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
ANTI-CD37 ANTIBODIES
|
US20100226925A1
(en)
*
|
2007-09-14 |
2010-09-09 |
Amgen Inc. |
Homogeneous Antibody Populations
|
EP3789400A1
(en)
|
2007-09-26 |
2021-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
EP2202245B1
(en)
|
2007-09-26 |
2016-08-24 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
GB0719231D0
(en)
|
2007-10-03 |
2007-11-14 |
Oxford Genome Sciences Uk Ltd |
Protein
|
AR068767A1
(en)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
|
JP5620106B2
(en)
*
|
2007-10-24 |
2014-11-05 |
株式会社糖鎖工学研究所 |
Polypeptide having enhanced effector function
|
KR20100091170A
(en)
|
2007-11-02 |
2010-08-18 |
노파르티스 아게 |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
|
CA3102704A1
(en)
|
2007-12-14 |
2009-06-25 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
EP3825329A1
(en)
|
2007-12-26 |
2021-05-26 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
EP2245065A1
(en)
*
|
2008-01-23 |
2010-11-03 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
CN101970006B
(en)
|
2008-02-05 |
2014-08-06 |
百时美施贵宝公司 |
Alpha 5 - beta 1 antibodies and their uses
|
SI2275443T1
(en)
|
2008-04-11 |
2016-03-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
CA2726845C
(en)
*
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
PL2310412T3
(en)
*
|
2008-06-20 |
2018-10-31 |
Novartis Ag |
Immunoglobulins with reduced aggregation
|
WO2009155518A1
(en)
|
2008-06-20 |
2009-12-23 |
Novartis Ag |
Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor
|
EP2307458B1
(en)
*
|
2008-06-25 |
2018-04-11 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Humanization of rabbit antibodies using a universal antibody framework
|
KR20210097819A
(en)
*
|
2008-06-25 |
2021-08-09 |
노바르티스 아게 |
Humanization of rabbit antibodies using a universal antibody framework
|
NZ600622A
(en)
|
2008-08-05 |
2013-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
US20100143353A1
(en)
*
|
2008-12-04 |
2010-06-10 |
Mosser David M |
POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
|
CA2745436A1
(en)
*
|
2008-12-05 |
2010-06-10 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
EP2373690B1
(en)
|
2008-12-08 |
2015-02-11 |
Compugen Ltd. |
Antibodies specific for tmem154
|
US20110319598A1
(en)
*
|
2008-12-17 |
2011-12-29 |
Xoma Technology Ltd. |
Methods and materials for determining isoelectric point
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
US20120020952A1
(en)
*
|
2009-01-26 |
2012-01-26 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
JP5816558B2
(en)
|
2009-03-05 |
2015-11-18 |
メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. |
Fully human antibody specific for CADM1
|
JP5883653B2
(en)
|
2009-03-10 |
2016-03-15 |
ベイラー リサーチ インスティテュートBaylor Research Institute |
Antigen-presenting cell targeting antiviral vaccine
|
CN102448989B
(en)
|
2009-03-10 |
2015-09-30 |
贝勒研究院 |
Anti-CD 40 antibodies and uses thereof
|
WO2010123012A1
(en)
*
|
2009-04-20 |
2010-10-28 |
協和発酵キリン株式会社 |
Antibody containing igg2 having amino acid mutation introduced therein
|
MA33276B1
(en)
|
2009-04-20 |
2012-05-02 |
Oxford Biotherapeutics Ltd |
Cadherine-17 antibodies
|
NO2424895T3
(en)
|
2009-04-27 |
2018-02-03 |
|
|
BRPI1016055A2
(en)
|
2009-04-27 |
2016-05-10 |
Novartis Ag |
composition and methods of use for il-12 receptor beta-subunit specific therapeutic antibodies
|
KR20170113704A
(en)
*
|
2009-05-13 |
2017-10-12 |
젠자임 코포레이션 |
Anti-human cd52 immunoglobulins
|
PL2896404T3
(en)
|
2009-06-04 |
2017-12-29 |
Novartis Ag |
Methods for identification of sites for IgG conjugation
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AU2009353265A1
(en)
*
|
2009-09-25 |
2012-05-17 |
Shanghai National Engineering Research Center Of Antibody Medicine Co., Ltd. |
Method of acquiring proteins with high affinity by computer aided design
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
EP2470569A1
(en)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
WO2011057198A1
(en)
|
2009-11-09 |
2011-05-12 |
Carson Cantwell G |
Vaccine testing system
|
CA2781539C
(en)
*
|
2009-11-23 |
2021-07-20 |
Amgen Inc. |
Monomeric antibody fc
|
EP2327725A1
(en)
*
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
US8937159B2
(en)
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
EP2516468B1
(en)
|
2009-12-23 |
2016-03-02 |
Synimmune GmbH |
Anti-flt3 antibodies and methods of using the same
|
CA2789629A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc. |
Cd20 antibodies and uses thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
BR112012024565B1
(en)
|
2010-03-26 |
2022-02-08 |
Trustees Of Dartmouth College |
FUSION PROTEIN VIEWED ISOLATED OR RECOMBINANT MULTIMERIC IMMUNOSUPPRESSANT AND COMPOSITION
|
EP2552957A4
(en)
*
|
2010-03-29 |
2013-11-20 |
Zymeworks Inc |
Antibodies with enhanced or suppressed effector function
|
ES2807217T3
(en)
|
2010-03-31 |
2021-02-22 |
Boehringer Ingelheim Int |
Anti-CD40 antibodies
|
BR112012026227A2
(en)
|
2010-04-13 |
2020-08-04 |
Celldex Therapeutics, Inc. |
human or humanized monoclonal antibody, bispecific molecule, expression vector, transformed cell, composition, and, uses of an antibody
|
EP3202789B1
(en)
|
2010-04-16 |
2020-05-06 |
Biogen MA Inc. |
Anti-vla-4 antibodies
|
EP2563812A4
(en)
*
|
2010-04-30 |
2016-01-13 |
Alexion Pharma Inc |
Antibodies having reduced immunogenicity in a human
|
EP4234698A3
(en)
|
2010-05-06 |
2023-11-08 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
PE20130206A1
(en)
|
2010-05-06 |
2013-02-28 |
Novartis Ag |
MULTIVALENT ANTIBODIES ANTAGONISTS OF LRP6 (LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6) AND COMPOSITIONS
|
RU2604811C2
(en)
|
2010-05-27 |
2016-12-10 |
Мерк Шарп Энд Домэ Корп. |
Method for preparing antibodies having improved properties
|
EP3327035A1
(en)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
EP4219805A1
(en)
*
|
2010-07-16 |
2023-08-02 |
Adimab, LLC |
Antibody libraries
|
EP2409989A1
(en)
*
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Method to improve glycosylation profile for antibody
|
CN105820256A
(en)
*
|
2010-07-28 |
2016-08-03 |
格利克尼克股份有限公司 |
Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin FC compositions
|
JP5964300B2
(en)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
Covalently bonded diabody and its use
|
JP6334166B2
(en)
*
|
2010-08-10 |
2018-05-30 |
グリコトープ ゲーエムベーハー |
Fab glycosylated antibody
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
MY162825A
(en)
|
2010-08-20 |
2017-07-31 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
US9068006B2
(en)
|
2010-08-25 |
2015-06-30 |
President And Fellows Of Harvard College |
Glycated CD59 peptides, their preparation, and uses thereof
|
EP2616100B1
(en)
|
2010-09-17 |
2016-08-31 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
CA3182320A1
(en)
|
2010-09-23 |
2012-03-29 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
UA112062C2
(en)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
CD33-Binding Agent
|
WO2012045703A1
(en)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
|
GB201016864D0
(en)
*
|
2010-10-06 |
2010-11-17 |
Univ Aston |
Therapeutic methods
|
WO2012064733A2
(en)
*
|
2010-11-09 |
2012-05-18 |
Medimmune, Llc |
Antibody scaffold for homogenous conjugation
|
AR083847A1
(en)
*
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
|
TWI654204B
(en)
|
2010-11-30 |
2019-03-21 |
中外製藥股份有限公司 |
Antibody with calcium-dependent antigen binding ability
|
US20140010812A1
(en)
*
|
2010-12-20 |
2014-01-09 |
Rockefeller University (The) |
Modulating agonistic tnfr antibodies
|
MX2013007392A
(en)
*
|
2010-12-22 |
2013-11-01 |
Cephalon Australia Pty Ltd |
Modified antibody with improved half-life.
|
CN103347898B
(en)
*
|
2011-01-10 |
2017-12-05 |
Ct大西洋有限公司 |
Including the therapeutic alliance with tumor associated antigen binding antibody
|
BR112013017980A2
(en)
|
2011-01-14 |
2017-06-27 |
Redwood Bioscience Inc |
aldehyde-labeled immunoglobulin polypeptides and method of use
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
MX352889B
(en)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Fcîriib-specific fc antibody.
|
PT2683406T
(en)
*
|
2011-03-11 |
2019-07-08 |
Beth Israel Deaconess Medical Ct Inc |
Anti-cd40 antibodies and uses thereof
|
US9527925B2
(en)
*
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
US9321833B2
(en)
|
2011-04-04 |
2016-04-26 |
The Trustees Of Dartmouth College |
Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
|
US9028826B2
(en)
|
2011-04-04 |
2015-05-12 |
The Trustees Of Dartmouth College |
Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
|
DK2697257T3
(en)
|
2011-04-13 |
2017-01-30 |
Bristol Myers Squibb Co |
FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
|
EP2697256A1
(en)
|
2011-04-15 |
2014-02-19 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
CN106928362B
(en)
|
2011-04-29 |
2021-10-26 |
埃派斯进有限公司 |
anti-CD 40 antibodies and methods of use thereof
|
DK3424953T3
(en)
|
2011-06-06 |
2020-11-02 |
Novo Nordisk As |
Terapeutiske antistoffer
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
EP2726508B1
(en)
|
2011-06-28 |
2017-08-09 |
Oxford BioTherapeutics Ltd |
Antibodies to adp-ribosyl cyclase 2
|
HUE033713T2
(en)
|
2011-06-28 |
2017-12-28 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
TWI687439B
(en)
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
Heterodimerized polypeptide
|
PL2726099T3
(en)
|
2011-07-01 |
2018-12-31 |
Novartis Ag |
Method for treating metabolic disorders
|
UA117901C2
(en)
*
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Antibody variants and uses thereof
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
GB2495113A
(en)
*
|
2011-09-29 |
2013-04-03 |
Bioinvent Int Ab |
Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
|
EP3939996A1
(en)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
EP2760471B9
(en)
|
2011-09-30 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
TW201326209A
(en)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
CN104080909A
(en)
|
2011-11-30 |
2014-10-01 |
中外制药株式会社 |
Drug containing carrier into cell for forming immune complex
|
EA201491107A1
(en)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN II HER3
|
KR102151383B1
(en)
|
2011-12-05 |
2020-09-03 |
노파르티스 아게 |
Antibodies for epidermal growth factor receptor 3 (her3)
|
EP2794656B1
(en)
|
2011-12-21 |
2019-02-27 |
Novartis AG |
Compositions comprising antibodies targeting factor p and c5
|
JP2015512616A
(en)
|
2012-02-01 |
2015-04-30 |
コンピュゲン エルティーディー. |
C1ORF32 antibody and its use for the treatment of cancer
|
CN113527469A
(en)
*
|
2012-02-09 |
2021-10-22 |
中外制药株式会社 |
Fc region variants of antibodies
|
US20190202898A9
(en)
*
|
2012-04-03 |
2019-07-04 |
Novelmed Therapeutics, Inc. |
AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
|
BR112014025299A8
(en)
|
2012-04-17 |
2018-01-16 |
Arsanis Biosciences Gmbh |
cross-reactive antibody directed against staphylococcus aureus, pharmaceutical and diagnostic preparation comprising the antibody, cross-reactive antibody methods against staphylococcus aureus
|
US9856323B2
(en)
*
|
2012-04-26 |
2018-01-02 |
Bioatla, Llc |
Anti-CD22 antibodies
|
US8992915B2
(en)
|
2012-05-16 |
2015-03-31 |
Boehringer Ingelheim International Gmbh |
Combination of CD37 antibodies with ICE
|
RU2743463C2
(en)
|
2012-05-30 |
2021-02-18 |
Чугаи Сейяку Кабусики Кайся |
Antigen-binding molecule specific to target tissue
|
WO2013187495A1
(en)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
US9732161B2
(en)
*
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
ES2758979T3
(en)
*
|
2012-07-06 |
2020-05-07 |
Genmab Bv |
Dimeric protein with triple mutations
|
WO2014006217A1
(en)
*
|
2012-07-06 |
2014-01-09 |
Genmab B.V. |
Dimeric protein with triple mutations
|
HRP20211641T1
(en)
|
2012-07-13 |
2022-02-04 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
CA2880007C
(en)
|
2012-07-25 |
2021-12-28 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US10431325B2
(en)
|
2012-08-03 |
2019-10-01 |
Novartis Ag |
Methods to identify amino acid residues involved in macromolecular binding and uses therefor
|
EP2885320A4
(en)
|
2012-08-20 |
2016-04-06 |
Gliknik Inc |
Molecules with antigen binding and polyvalent fc gamma receptor binding activity
|
JP6774164B2
(en)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
Mouse FcγRII specific Fc antibody
|
NZ705370A
(en)
|
2012-08-24 |
2018-06-29 |
Chugai Pharmaceutical Co Ltd |
Fcγriib-specific fc region variant
|
CN109793893B
(en)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
VISTA modulators for diagnosis and treatment of cancer
|
CN109265552A
(en)
|
2012-10-30 |
2019-01-25 |
埃派斯进有限公司 |
Anti-CD 40 antibodies and its application method
|
HUE053669T2
(en)
|
2012-12-05 |
2021-07-28 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
MX2015007931A
(en)
|
2012-12-18 |
2015-10-05 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan.
|
TWI693073B
(en)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
|
US10766960B2
(en)
|
2012-12-27 |
2020-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
WO2014106176A1
(en)
|
2012-12-28 |
2014-07-03 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
JP6553517B2
(en)
|
2013-01-17 |
2019-07-31 |
アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
MDR E. coli specific antibody
|
EP2953969B1
(en)
|
2013-02-08 |
2019-08-28 |
Novartis AG |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
WO2014126871A1
(en)
|
2013-02-12 |
2014-08-21 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2956467B1
(en)
|
2013-02-12 |
2017-09-27 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
JP6676521B2
(en)
|
2013-03-14 |
2020-04-08 |
マクロジェニクス,インコーポレーテッド |
Bispecific molecules, pharmaceutical compositions and uses thereof
|
AR095199A1
(en)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
ANTI-CD52 ANTIBODIES
|
AU2014228502A1
(en)
|
2013-03-15 |
2015-08-20 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
ES2699599T3
(en)
*
|
2013-03-15 |
2019-02-11 |
Abbvie Biotherapeutics Inc |
Fc variants
|
EP3783017A1
(en)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
EP2994164B1
(en)
|
2013-05-08 |
2020-08-05 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
US20160108106A1
(en)
|
2013-05-21 |
2016-04-21 |
Arsanis Biosciences Gmbh |
Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
|
EP3004174B1
(en)
|
2013-05-31 |
2019-04-17 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
AR096601A1
(en)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
|
US10150814B2
(en)
*
|
2013-06-27 |
2018-12-11 |
Abbvie Biotherapeutics Inc. |
Fc variants with improved complement activation
|
ES2865473T3
(en)
*
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Antibodies Comprising Multiple Site-Specific Unnatural Amino Acid Residues, Methods for Their Preparation, and Methods of Use
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(en)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
|
CA2918300A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
DK3050896T3
(en)
|
2013-09-27 |
2021-07-19 |
Chugai Pharmaceutical Co Ltd |
Process for the preparation of a polypeptide heteromultimer
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
WO2015051010A1
(en)
|
2013-10-02 |
2015-04-09 |
Medimmune, Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
JP6473746B2
(en)
|
2013-10-17 |
2019-02-20 |
アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
Cross-reactive S. aureus antibody sequence
|
CA2930307A1
(en)
|
2013-11-13 |
2015-05-21 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
CN105980409B
(en)
|
2013-11-27 |
2023-07-18 |
酵活生物制药有限公司 |
Bispecific antigen binding constructs targeting HER2
|
KR20160090904A
(en)
|
2013-12-06 |
2016-08-01 |
다나-파버 캔서 인스티튜트 인크. |
Therapeutic peptides
|
CN105829347B
(en)
|
2013-12-20 |
2020-09-08 |
豪夫迈·罗氏有限公司 |
Bispecific HER2 antibodies and methods of use
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR102534681B1
(en)
|
2013-12-24 |
2023-05-18 |
잔센파마슈티카엔.브이. |
Anti-vista antibodies and fragments
|
US10286058B2
(en)
|
2014-01-13 |
2019-05-14 |
Baylor Research Institute |
Vaccines against HPV and HPV-related diseases
|
SG10202104175YA
(en)
*
|
2014-02-27 |
2021-06-29 |
Allergan Inc |
COMPLEMENT FACTOR Bb ANTIBODIES
|
GB201403775D0
(en)
*
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
US10279021B2
(en)
|
2014-03-14 |
2019-05-07 |
Dana-Faber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring NKG2D pathway function against cancers
|
TW201622746A
(en)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
Methods of improving or accelerating physical recovery after surgery for hip fracture
|
KR102409014B1
(en)
|
2014-05-08 |
2022-06-14 |
추가이 세이야쿠 가부시키가이샤 |
Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
|
BR112016026299A2
(en)
|
2014-05-13 |
2018-02-20 |
Chugai Seiyaku Kabushiki Kaisha |
The T-lymph cell redirection antigen joint molecule to the cell which has an immunosuppressive function
|
EP3145543A4
(en)
|
2014-05-23 |
2017-12-13 |
Celldex Therapeutics, Inc. |
Treatment of eosinophil or mast cell related disorders
|
EA037006B1
(en)
|
2014-06-06 |
2021-01-26 |
Бристол-Майерс Сквибб Компани |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2015191881A2
(en)
|
2014-06-11 |
2015-12-17 |
Green Kathy A |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
GB201413665D0
(en)
|
2014-07-03 |
2014-09-17 |
Transimmune Ag And Yale University |
Method for obtaining globally activated monocytes
|
CN113563462A
(en)
|
2014-07-15 |
2021-10-29 |
免疫医疗有限责任公司 |
Neutralizing anti-influenza b antibodies and uses thereof
|
BR112016030462A2
(en)
|
2014-08-04 |
2018-01-16 |
F. Hoffmann-La Roche Ag |
binding molecules, one or more isolated polynucleotides, one or more vectors, host cell, method of producing a binding molecule, pharmaceutical composition, use of the binding molecule, method of treating disease and inducing target cell lysis
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
CU24453B1
(en)
|
2014-08-07 |
2019-11-04 |
Novartis Ag |
ANTI-PROTEIN ANTIBODIES SIMILAR TO ANGIOPOYETIN 4
|
KR102443258B1
(en)
|
2014-08-12 |
2022-09-14 |
엘리게이터 바이오사이언스 에이비 |
Combination therapies with anti cd40 antibodies
|
MA40764A
(en)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
BR112017006515A8
(en)
|
2014-09-29 |
2018-02-27 |
Univ Duke |
bispecific molecules, compositions, method for treating or preventing HIV-1 infection in an individual with this need, and vector
|
KR20230125855A
(en)
|
2014-11-21 |
2023-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies against cd73 and uses thereof
|
EP3026060A1
(en)
*
|
2014-11-26 |
2016-06-01 |
Miltenyi Biotec GmbH |
Humanized antibody or fragment thereof specific for CD45R0
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
US20160168237A1
(en)
*
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
UY36449A
(en)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
|
US9765135B2
(en)
|
2014-12-19 |
2017-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies
|
KR101860280B1
(en)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
MA41459A
(en)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
|
KR20170110129A
(en)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use
|
AU2016219511B2
(en)
*
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
CN107371365B
(en)
|
2015-02-17 |
2022-01-11 |
X4制药(奥地利)有限责任公司 |
Antibody targeting Klebsiella pneumoniae galactoglycan O-antigen
|
US9512229B2
(en)
*
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
ES2937020T3
(en)
*
|
2015-03-03 |
2023-03-23 |
Kymab Ltd |
Antibodies, uses and methods
|
US11142587B2
(en)
*
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
CN107873034A
(en)
|
2015-04-17 |
2018-04-03 |
阿尔萨尼斯生物科学有限责任公司 |
Anti-staphylococcus aureus antibody combination preparation
|
SG11201708323SA
(en)
|
2015-04-30 |
2017-11-29 |
Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
CN108137687B
(en)
|
2015-05-29 |
2021-10-29 |
百时美施贵宝公司 |
anti-OX 40 antibodies and uses thereof
|
PE20180193A1
(en)
*
|
2015-05-29 |
2018-01-26 |
Abbvie Inc |
ANTI-CD40 ANTIBODIES AND THEIR USES
|
SG11201707815RA
(en)
|
2015-06-05 |
2017-12-28 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
TWI773646B
(en)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
Lag-3-binding molecules and methods of use thereof
|
BR112017027870A2
(en)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
antibodies and anti-sight fragments
|
JOP20200312A1
(en)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
Factor xi antibodies and methods of use
|
KR20180021833A
(en)
*
|
2015-06-29 |
2018-03-05 |
더 락커펠러 유니버시티 |
Antibodies to CD40 with enhanced agonist activity
|
US11376326B2
(en)
|
2015-07-01 |
2022-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
|
CA2994516A1
(en)
|
2015-08-03 |
2017-02-09 |
Novartis Ag |
Methods of treating fgf21-associated disorders
|
WO2017027858A1
(en)
|
2015-08-12 |
2017-02-16 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating volume depletion and kidney injury
|
EP3307322B1
(en)
|
2015-09-04 |
2021-02-17 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
WO2017042701A1
(en)
|
2015-09-09 |
2017-03-16 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
LT3347377T
(en)
|
2015-09-09 |
2021-05-25 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
ES2906823T3
(en)
|
2015-09-30 |
2022-04-20 |
Janssen Biotech Inc |
Agonist antibodies that specifically bind to human CD40 and methods of use
|
CA3000901A1
(en)
|
2015-10-16 |
2017-04-20 |
Arsanis Biosciences Gmbh |
Bactericidal monoclonal antibody targeting klebsiella pneumoniae
|
EP3378488A4
(en)
*
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
JP6931329B2
(en)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
KR20180089510A
(en)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
Antibodies targeting CD32b and methods of using the same
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
WO2017115773A1
(en)
|
2015-12-28 |
2017-07-06 |
中外製薬株式会社 |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
AU2017212739B2
(en)
|
2016-01-27 |
2024-03-21 |
Sutro Biopharma, Inc. |
Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
|
BR112018016461A2
(en)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
antibodies and anti-sight fragments, their uses and their identification methods
|
KR20230038311A
(en)
|
2016-03-04 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
Combination therapy with anti-cd73 antibodies
|
MX2018010672A
(en)
|
2016-03-04 |
2019-05-27 |
Univ Rockefeller |
Antibodies to cd40 with enhanced agonist activity.
|
CN116284392A
(en)
|
2016-03-10 |
2023-06-23 |
艾科赛扬制药股份有限公司 |
Activin type 2 receptor binding proteins and uses thereof
|
SG10202007025PA
(en)
|
2016-03-14 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
CR20180537A
(en)
|
2016-04-15 |
2019-03-04 |
Immunext Inc |
ANTIHUMAN VIEW ANTIBODIES AND THEIR USE
|
AU2017249435A1
(en)
|
2016-04-15 |
2018-10-25 |
Macrogenics, Inc. |
Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
CA3021328A1
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
JP2019515677A
(en)
|
2016-04-26 |
2019-06-13 |
アール.ピー.シェーラー テクノロジーズ エルエルシー |
Antibody conjugates and methods of making and using the same
|
WO2017189724A1
(en)
|
2016-04-27 |
2017-11-02 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
TW201802121A
(en)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
|
AU2017279538A1
(en)
|
2016-06-07 |
2019-01-03 |
Gliknik Inc. |
Cysteine-optimized stradomers
|
CA3026880A1
(en)
|
2016-06-08 |
2017-12-14 |
Paul Foster |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
JP7231411B2
(en)
|
2016-06-15 |
2023-03-01 |
ノバルティス アーゲー |
Methods of treating diseases using inhibitors of bone morphogenetic protein 6 (BMP6)
|
US10077306B2
(en)
|
2016-07-14 |
2018-09-18 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
EP3494141A4
(en)
|
2016-08-03 |
2020-04-08 |
Bio-Techne Corporation |
Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
|
WO2018025982A1
(en)
|
2016-08-05 |
2018-02-08 |
中外製薬株式会社 |
Composition for prophylaxis or treatment of il-8 related diseases
|
JP2019531708A
(en)
|
2016-08-12 |
2019-11-07 |
エックスフォー・ファーマシューティカルズ(オーストリア)ゲーエムべーハー |
Klebsiella pneumoniae O3-specific antibody
|
JP2019531060A
(en)
|
2016-08-12 |
2019-10-31 |
エックスフォー・ファーマシューティカルズ(オーストリア)ゲーエムべーハー |
Anti-galactan-II monoclonal antibody targeting Klebsiella pneumoniae
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
EP3524624A4
(en)
*
|
2016-09-29 |
2020-06-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-cd27 antibody, antigen-binding fragment thereof, and medical use of same
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
AU2017353939A1
(en)
|
2016-11-07 |
2019-06-06 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
WO2018087720A1
(en)
|
2016-11-14 |
2018-05-17 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
AU2017363309A1
(en)
|
2016-11-23 |
2019-07-11 |
Bioverativ Therapeutics Inc. |
Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
|
EP3551647A4
(en)
|
2016-12-09 |
2021-01-13 |
Gliknik Inc. |
Manufacturing optimization of gl-2045, a multimerizing stradomer
|
CA3043251A1
(en)
|
2016-12-09 |
2018-06-14 |
Gliknik Inc. |
Methods of treating inflammatory disorders with multivalent fc compounds
|
CN110325550B
(en)
|
2016-12-23 |
2024-03-08 |
诺华股份有限公司 |
Factor XI antibodies and methods of use
|
TW201825515A
(en)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met antibodies and immunoconjugates and uses thereof
|
WO2018129425A1
(en)
*
|
2017-01-06 |
2018-07-12 |
Igc Bio, Inc. |
System and method for generating antibody libraries
|
AU2018215673A1
(en)
*
|
2017-02-06 |
2019-07-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for augmenting antibody mediated receptor signaling
|
JP6991246B2
(en)
|
2017-02-08 |
2022-02-03 |
ノバルティス アーゲー |
FGF21 mimetic antibody and its use
|
CA3052837A1
(en)
|
2017-02-28 |
2018-09-07 |
Seattle Genetics, Inc. |
Cysteine mutated antibodies for conjugation
|
US11127483B2
(en)
|
2017-03-07 |
2021-09-21 |
Igc Bio, Inc. |
Computational pipeline for antibody modeling and design
|
US10982000B2
(en)
|
2017-03-24 |
2021-04-20 |
Novartis Ag |
Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
JP2020515643A
(en)
|
2017-04-03 |
2020-05-28 |
インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングInflaRx GmbH |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
CN110352201A
(en)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
The subcutaneous administration of antibody drug conjugate for cancer therapy
|
KR20190137821A
(en)
*
|
2017-04-07 |
2019-12-11 |
아이쥐엠 바이오사이언스 인코포레이티드 |
Modified Human IgM Constant Region for Modulation of Complement-Dependent Cytolytic Effector Function
|
US11634495B2
(en)
*
|
2017-04-07 |
2023-04-25 |
Miltenyi Biotec B.V. & Co. KG |
Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
|
CN107056937A
(en)
*
|
2017-04-11 |
2017-08-18 |
同济大学 |
A kind of method based on the direct designerantibodies hypervariable region sequence of epitope structure
|
SG10202111207TA
(en)
*
|
2017-05-24 |
2021-11-29 |
Als Therapy Development Inst |
Therapeutic anti-cd40 ligand antibodies
|
US20200299400A1
(en)
*
|
2017-05-25 |
2020-09-24 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
AU2018279950A1
(en)
|
2017-06-09 |
2020-01-30 |
President And Fellows Of Harvard College |
Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CA3063659A1
(en)
|
2017-06-28 |
2019-01-03 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
PT3658184T
(en)
|
2017-07-27 |
2023-11-29 |
Alexion Pharma Inc |
High concentration anti-c5 antibody formulations
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-cd200 therapy
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
CN111902427A
(en)
|
2017-11-22 |
2020-11-06 |
诺华股份有限公司 |
Reverse binding agents to anti-factor XI/XIa antibodies and uses thereof
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
US11787857B2
(en)
|
2018-02-02 |
2023-10-17 |
Bio-Techne Corporation |
Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
|
MX2020009296A
(en)
|
2018-03-15 |
2020-11-13 |
Chugai Pharmaceutical Co Ltd |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use.
|
KR20200135830A
(en)
|
2018-03-23 |
2020-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies against MICA and/or MICB and uses thereof
|
US20210214445A1
(en)
|
2018-03-23 |
2021-07-15 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
MX2020009975A
(en)
|
2018-03-28 |
2020-10-12 |
Bristol Myers Squibb Co |
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use.
|
US20210198374A1
(en)
|
2018-04-17 |
2021-07-01 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
TW202402806A
(en)
|
2018-05-18 |
2024-01-16 |
日商第一三共股份有限公司 |
Anti-muc1 antibody-drug conjugate
|
UY38247A
(en)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CA3107383A1
(en)
*
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
TW202039586A
(en)
|
2018-12-18 |
2020-11-01 |
瑞士商諾華公司 |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
US20220073619A1
(en)
|
2018-12-26 |
2022-03-10 |
Imcheck Therapeutics Sas |
Btn3a binding proteins and uses thereof
|
JP7285936B2
(en)
|
2019-01-22 |
2023-06-02 |
ブリストル-マイヤーズ スクイブ カンパニー |
Antibodies against IL-7R alpha subunit and uses thereof
|
JP7370391B2
(en)
|
2019-03-18 |
2023-10-27 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
Bioconjugate of Escherichia coli O antigen polysaccharide, its production method and its use method
|
JP2022548881A
(en)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
US20210130440A1
(en)
*
|
2019-10-03 |
2021-05-06 |
Janssen Biotech, Inc. |
Methods for producing biotherapeutics with increased stability by sequence optimization
|
AR121462A1
(en)
*
|
2020-02-28 |
2022-06-08 |
Genzyme Corp |
MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION
|
UY39324A
(en)
|
2020-07-16 |
2022-02-25 |
Novartis Ag |
ANTI-BETACELLULIN ANTIBODIES, THEIR FRAGMENTS, MULTISPECIFIC BINDING MOLECULES, EXPRESSION CASSETTES, COMPOSITIONS AND TREATMENT METHODS.
|
TW202233684A
(en)
*
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
Heavy chain antibodies binding to folate receptor alpha
|
JP2024514530A
(en)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Antibodies against truncated CDCP1 and uses thereof
|
WO2022272283A1
(en)
*
|
2021-06-24 |
2022-12-29 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Dual egfr-muc1 chimeric antigen receptor t cells
|
WO2023110045A1
(en)
*
|
2021-12-15 |
2023-06-22 |
Y-Mabs Therapeutics, Inc. |
Scfv and antibodies with reduced multimerisation
|
US20230365708A1
(en)
|
2022-04-01 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023217743A1
(en)
|
2022-05-10 |
2023-11-16 |
Imcheck Therapeutics |
Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders
|